About X4 Pharmaceuticals (XFOR)

X4 Pharmaceuticals Inc (XFOR) is a biotechnology company that focuses on the discovery and development of novel small molecule therapeutics for the treatment of rare diseases. The company's lead product candidate, X4P-001, is being evaluated in multiple clinical trials for the treatment of various rare primary immunodeficiency diseases. X4P-001 is a potential first-in-class oral therapy that targets the CXCR4 pathway, which plays a critical role in the immune system and is involved in the pathogenesis of several rare diseases. The company's pipeline also includes X4P-002, a potential treatment for solid tumors, and X4P-003, a potential treatment for hematologic malignancies.

X4 Pharmaceuticals Inc's stock price has experienced significant fluctuations over the past year. As of the latest available data, the stock is trading at $10.50 per share. The 52-week range for XFOR stock is $7.25 to $13.50. The stock has a market capitalization of approximately $200 million. In terms of valuation, X4 Pharmaceuticals Inc has a PEG ratio of N/A, as earnings growth estimates are not available at this time. In comparison to the industry, XFOR stock has performed relatively well, outperforming some of its peers. However, it is important to note that investing in biotechnology stocks involves inherent risks and investors should carefully consider their investment objectives and risk tolerance before investing in X4 Pharmaceuticals Inc or any other biotechnology company.